FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis in patients aged 6 and older

Reuters02-24 22:30
FDA approves <a href="https://laohu8.com/S/GCVRZ">Sanofi</a> and Regeneron’s Dupixent for allergic fungal rhinosinusitis in patients aged 6 and older

Sanofi SA and Regeneron Pharmaceuticals said the US Food and Drug Administration approved Dupixent (dupilumab) to treat allergic fungal rhinosinusitis in adults and children aged 6 years and older who have a history of sino-nasal surgery. The approval was supported by the phase 3 LIBERTY-AFRS-AIMS study and was reviewed under the FDA’s priority review program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240930OMX_____CNEWS_EN_GNW1001166459_en) on February 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment